ICON Central Laboratories Launches New Cytometry Services Offering
ICON
announced the launch of a new Cytometry Services offering from its Central Laboratories business unit. ICON Cytometry Services now offers clients two types of services to better support the testing requirements and development phase of a client’s compound.
ICON Cytometry Services’ full service solution allows clients to collaborate with ICON at the early stages of development to create compound-specific assays. Clients work with ICON Central Laboratories’ R&D team to develop a unique Flow Cytometry methodology, customised SOPs and agree on other special requirements including reporting. These customised Flow Cytometry panels can then be used throughout the compound development lifecycle. ICON Cytometry Services’ other service offering enables clients to choose from a wide range of fully validated assays and is often suited to the large scale, high-volume requirements of later phase global trials.
Commenting on the announcement, Tom O’Leary, President, ICON Central Laboratories, said, “Flow Cytometry has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialised testing. Our new Cytometry Services offering provides clients with a better range of options, all of which are supported by a team of highly experienced scientists, robust instrumentation and rigorous quality control systems.”
ICON Central Laboratories offers global Flow Cytometry services from its laboratories in New York, Dublin, Bangalore and Singapore.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
